Ex vivo micro‑tumor testing
Accurately predicting clinical responses requires models that faithfully recapitulate the tumor microenvironment. VitroScan’s ex vivo micro‑tumor platform preserves native architecture, cellular heterogeneity, and stromal interactions of the patients’ tissues to deliver highly representative assays. By cultivating these patient-derived micro‑tumors in a physiologically relevant 3D matrix, our platform enables simultaneous evaluation of drug efficacy, resistance mechanisms, and combination strategies under conditions that closely mirror in‑situ disease.
Key attributes of the VitroScan micro‑tumor platform:
- Patient‑specific: Micro-tumors are derived directly from surgical or biopsy specimens, and immediately tested, thereby preserving the original profile of each patient’s malignancy and immune cells.
- Physiological relevance: The 3D matrix replicates extracellular matrix interactions and nutrient diffusion, supporting authentic cell‑cell and cell‑matrix signaling pathways.
- High‑throughput capacity: Miniaturized micro‑tumor arrays enable parallel testing of multiple therapeutics and combinations thereof, delivering statistically robust results within days.
- Therapeutic modalities: The predictive algorithms generate precise read‑outs of how patients will respond to standard‑of‑care treatments. Simultaneously, the ex vivo efficacy for novel therapies such as antibody‑drug conjugates (ADCs), immune therapies like bispecific antibodies and combination regimens is assessed.
- Quantitative results: Integrated imaging, tumor killing measurements and immune cell activation profiling generates comprehensive datasets, including dose‑response curves, biomarker profiling, and pathway activation to support data‑driven decisions.
- Regulatory‑ready validation: Built on stringent reproducibility and ISO-compatible standards, the platform delivers high-quality data suitable for academic, clinical and industry settings.
For clinicians and patients, the platform provides actionable insights to support personalized treatment decisions, thereby improving treatment outcomes while minimizing exposure to ineffective therapies.
For pharmaceutical partners, the platform offers high‑quality translational and IND enabling data in the drug development process, reducing attrition, accelerating go/no‑go decisions, and informing the development of next‑generation oncology therapeutics.
VitroScan’s ex vivo micro‑tumor testing brings together precision patient testing and innovative drug development, empowering stakeholders to confront cancer with unprecedented predictive confidence.
Info Sheets
Download Our latest scientific publication at a glance!
Koedoot et al., npj Precision Oncology, 2025
Download